Kornimate/medical-research-clean huggingface dataset:
a study of the correlation between portal vein thrombosis and prognosis of liver transplantation

Conditions: Portal Vein Thrombosis

Summary: the goal of this observational study is to investigate the correlation between portal vein thrombosis (pvt) and the prognosis of liver transplantation. the main questions it aims to address are: what is the prevalence of pvt? what are the risk factors associated with pvt? what is the prognostic impact of preoperative pvt on liver transplantation? participants are divided into two groups: the pvt group and the non-pvt group. the investigators will comparatively analyze the data of both groups, estimate the prevalence and risk factors of pvt, construct a predictive model for pvt that is applicable in clinical settings, and clarify the prognostic effects of pvt.

the investigators aim to investigate the prevalence and risk factors of pvt, to develop a novel grading or rating system for pvt, and to explore the prognostic impact of preoperative pvt in liver transplantation. the investigators will: recruit patients according to the inclusion/exclusion criteria and obtain signed informed consents. they will collect demographic and laboratory characteristics and classify patients into the pvt group and the non-pvt group based on preoperative ultrasound and/or computed tomography. collect patients' perioperative medical imaging, surgical procedures, pathology reports, postoperative treatments, follow-up data, and clinical endpoints. comparatively analyze the data of the pvt and non-pvt groups, estimate the prevalence and risk factors of pvt, construct a predictive model for pvt that is applicable in clinical settings, clarify the prognostic effects of pvt, and propose a grading/rating system for pvt.

Eligibility criteria:
inclusion criteria: 1. liver transplantation recipients 2. aged 18 years or older. exclusion criteria: 1. retransplantation 2. multi-organ transplantation 3. portal vein tumor thrombus
alopecia prevention scalp cooling in chinese breast cancer patients

Conditions: Breast Cancer

Summary: the orbis paxman hair loss prevention system is a new equipment introduced to hong kong in 2017. although this device has been widely used in the united states, europe and australia, acceptability, efficacy and safety data in chinese have not yet been available. the objective of this prospective study is to collect clinical data in chinese patients using the orbis paxman hair loss prevention system to prevent chemotherapy-induced alopecia. this project seeks to demonstrate that the orbis paxman hair loss prevention system is safe and effective in reducing chemotherapy-induced alopecia in woman with breast cancer undergoing neoadjuvant or adjuvant chemotherapy.


Eligibility criteria:
inclusion criteria: i) new diagnosis of breast cancer stage i-iii ii) chinese ethnicity iii) ecog 0-1 iii) planning to undergo neoadjuvant or adjuvant chemotherapy with curative intent iv) chemotherapy must be planned for at least 4 cycles of full-dose anthracycline and/or taxane based chemotherapy regimen, 1. defined as one of the following regimens: * adriamycin 60 mg/m2 with cyclophosphamide 600 mg/m2 for 4 cycles (ac) \> 5-fluorouracil 500 mg/m2, epirubicin 100mg/m2, and cyclophosphamide 500 mg/m2 for 3 cycles, followed by docetaxel 100 mg/m2 for 3 cycles (fec-d) * ac x 4 cycles, followed by docetaxel 100 mg/m2 for 4 cycles (ac-d) * ac x 4 cycles, followed by paclitaxel 175 mg/m2 for 4 cycles (ac-p) * docetaxel 75 mg/m2 with cyclophosphamide 600 mg/m2 for 4-6 cycles (dc) * docetaxel 75 mg/m2 with carboplatin auc of 5-6 for 4-6 cycles (dcb) 2. concurrent trastuzumab and/or pertuzumab at standard doses is allowed. 3. administration of chemotherapy on a dose dense schedule with gcsf is allowed. v) adequate organ functions vi) normal thyroid stimulating hormone vii) subjects with history of diabetes must have acceptable hba1c on study entry viii) subjects who provide consent and are mentally competent and able to fill in study questionnaires exclusion criteria: i) subjects with any other concurrent malignancy including hematological malignancies (i.e. leukemia or lymphoma) ii) subjects with cold agglutinin disease or cold urticaria iii) age ≥ 70 years iv) personal history of migraines, cluster or tension headaches as defined as actual medical diagnosis by a physician and/ or prescribed medications. if personal history of migraines was related to a past medical problem that is now resolved, subject may go on study at the discretion of the principal investigator. v) elevated liver enzymes or bilirubin defined as 3 times the upper limits of normal vi) serum albumin \< 3.0 vii) subjects with anemia (defined as a hemoglobin \< 10) viii) subjects who have lichen planus or lupus, or other dermatological conditions involving scalp ix) subjects who are underweight (defined as a bmi \< 18.5) x) subjects who have had previous chemotherapy exposure
vitamin insufficiency in esophagogastric neoplasms

Conditions: Esophageal Cancer; Gastric Cancer; Vitamin Disease; Quality of Life

Summary: rationale: esophageal cancer and gastric cancer are among the top ten most common cancers worldwide. both diseases have major impact on the nutritional status of patients and their quality of life. studies investigating post-operative nutritional status are limited and postoperative identification and treatment of micro- and macronutritional deficiencies are currently lacking in (inter-)national guidelines. objective: to identify and target vitamin deficiencies after surgery for esophagogastric neoplasms. study design: single centre intervention study. study population: patients aged 18 years and older that underwent esophagectomy or (sub- )total gastrectomy for esophagogastric neoplasms. intervention (if applicable): two tailormade supplements for patients; one for that underwent esophagectomy and one for (sub-)total gastrectomy. main study parameters/endpoints: baseline micronutrient deficiency measurements and after 6, 12, 24 months supplementation,. secondary study parameters/ endpoints: occurrence of exocrine pancreatic insufficiency (n,%), occurrence of diarrhoea (n,%), steatorrhea (n,%), bloating (n,%), time between surgery and start of supplementation (mean in months), quality of life experienced (questionnaires) at baseline and after 6, 12, 24 months supplementation. nature and extent of the burden and risks associated with participation, benefit and group relatedness: in this study, no health-related risks are present for participants due to the administration of supplementation that is already used as in clinical practice.


Eligibility criteria:
inclusion criteria: a potential subject who meets any of the following criteria will be included for participation in this study: * patients ≥18 years of age who underwent an esophagectomy or (sub)total gastrectomy for malignancy with no signs of postoperative recurrence of disease. * written voluntary informed consent (ic). exclusion criteria: - a potential subject who meets any of the following criteria will be excluded from participation in this study: * patients that underwent a wedge resection of the stomach * malignant disease recurrence * metastases * patients that are not capable to take supplementation due to altered mental status or swallow difficulties * no signed informed consent * patients who are receiving chemotherapy * patients with high vitamin status at baseline
molecular and epidemiological characteristics of endometrial cancer in brazil

Conditions: Endometrial Cancer

Summary: an evaluation of the molecular and epidemiological aspects of endometrial cancer in brazil is necessary to understand the high frequency of advanced disease. a better understanding of the current situation will generate essential data for the future development of national or international cooperative programs that aim to improve outcomes in these patients and generate additional knowledge for much-needed clinical trials in this population.

this is a retrospective observational cohort study. in this study, we will include patients diagnosed with endometrium cancer from january 2016 to december 2019 in participating sites and collect data on demographics, clinicopathological characteristics, treatment patterns, and outcomes. data will be collected from medical records in selected centers that comprise different regions of brazil. the patient data sources will be the medical records of the patients. patients will continue to receive treatment and clinical evaluations for endometrial cancer according to what is determined by their medical team, according to the usual standards of treatment and clinical practice of each center. to minimize patient selection bias, physicians should invite all consecutive eligible patients. this study also provides for the collection and archiving of tumor tissue material. the samples will be tested to characterize the molecular subtype of endometrial cancer and will be sequentially stored in a biorepository to enable future translational studies, according to national regulations.

Eligibility criteria:
inclusion criteria: * women ≥18 years * histological diagnosis of endometrial carcinoma. * diagnosis of endometrial cancer between january 2016 and december 2019. * figo (international federation of gynecology and obstetrics, 2018) stage i - iv. * site and investigator with access to a medical record chart from which data can be abstracted. * presence of a sample of tumor tissue (primary tumor or metastasis) available for biomarker testing. exclusion criteria: * noninvasive endometrial cancer. * patients with a history of concurrent or previously treated non-endometrial malignancies except for appropriately treated 1) non -metastatic non-melanoma skin cancer and/or 2) non-metastatic low-grade thyroid tumors and/or 3) in situ carcinomas, including cervix, colon, and skin. * nonepithelial histology (leiomyosarcoma, adenosarcoma, endometrial stromal sarcoma, undifferentiated sarcoma, or other mesenchymal tumors.
evaluation of the safety and efficacy of an injectable liposomal gel

Conditions: Skin Aging; Skin Wrinkling; Facial Skin Laxity; Facial Wrinkles

Summary: the aim of this study is to evaluate the efficacy and safety of intradermal injections of the medical device - hyaluronic acid with the addition of lecithin - in a population of participants with thin, dry, and sagging facial skin.

a total of 36 participants are planned to be enrolled in the study (18 in each group: group 1 - product administration using a needle; group 2 - product administration using a cannula). the primary endpoint will be the change in facial skin thickness resulting from three administrations of the densistim product, assessed no later than 8 weeks after the last procedure, based on ultrasound (us) measurements. ultrasound measurements will also be compared between visits and between study arms. changes in aesthetic improvement will be assessed by both the participant and the investigator. the safety of the investigational medical device will also be evaluated.

Eligibility criteria:
inclusion criteria: 1. female sex; 2. age over 18 years; 3. caucasian race; 4. thin, dry, and sagging facial skin; 5. signing an informed consent form; 6. commitment to refrain from undergoing facial therapies that may affect skin condition; 7. negative pregnancy test result and commitment to use a contraceptve method; exclusion criteria: 1. scars, birthmarks, or tattoos on the face that could interfere with the assessment of skin condition; 2. presence of open wounds, ulcers, active infections, or other significant skin damage at the planned injection site; 3. receipt of intradermal facial injections with native hyaluronic acid, platelet-rich plasma, or other injectable therapies within 6 months prior to study initiation; 4. receipt of intradermal facial injections with slowly absorbable or non-absorbable filler products within 12 months prior to study initiation; 5. known hypersensitivity to any component of the investigational product; 6. dermatitis or dermatological disease of inflammatory and/or infectious nature at the planned injection site; 7. history of cancer, autoimmune disease, or immunodeficiency; 8. use of medications affecting blood coagulation; 9. use of topical antihistamines, corticosteroids, or retinoids on the face within 4 weeks prior to the study; 10. pregnancy or breastfeeding; 11. participation or planned participation in other clinical trials;

Keywords: hyaluronic acid skin biostimulation intradermal injection facial skin rejuvenation dry skin thin skin skin rejuvenation
estimate rate of the women who have gestational diabetes

Conditions: Diabetes, Gestational

Summary: retrospective study to estimate screening of the type 2 diabetes of women who had childbirth in the hospital center rene dubos and having gestational diabetes.

it is recognized that pregnant women who had gestational diabetes (dg) multiplied by 7 subsequent risk of developing type 2 diabetes and this during 25 years. there is at present no formal recommendation of the high authority for health (has) as an organization of a long term screening for those women. however the recommendations of cngof (french council of gynaecologists and obstetricians) and sfd (french society of diabetes) recommend screening for type 2 diabetes after a gestational diabetes in the postnatal consultation. but today how many women views due to a gestational diabetes have realized their screening? it is likely that the rate of occurrence of type 2 diabetes after gestational diabetes is underestimated today. otherwise it is possible that the occurrence of type 2 diabetes is associated with some risk factors such as high bmi, insulin therapy during pregnancy. another interrogation is the role of the doctor to reduce the number of women who do not realize their screening at 3 months postpartum. better awareness of the importance of long term monitoring would reduce the proportion of women who do not realize their screening.

Eligibility criteria:
inclusion criteria: * participants aged over 18 years * participants who deliver between 01/01/2013 and 30/06/2015 * participants who have had a gestational diabetes * participants who have been informed and have returned the questionary exclusion criteria: * participants who do not wishing to participate in the study
rospa - record on satisfaction of patients with actonel 35 mg once a week

Conditions: Osteoporosis

Summary: to determine the satisfaction of subject with actonel 35 mg once a week in the treatment of post-menopausal osteoporosis. open, non-controlled, multi-center study.


Eligibility criteria:
inclusion criteria : * postmenopausal ambulatory women * established osteoporosis exclusion criteria: * history of cancer: basal cell or squamous cell carcinoma-documented 6-month remission, * diagnosis of hypocalcemia, hyperparathyroidism, hyperthyroidism the above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.
cilostazol and methotrexate in rheumatoid arthritis

Conditions: Rheumatoid Arthritis

Summary: this study aims at evaluating the therapeutic effects of cilostazol as adjuvant therapies to low dose of methotrexate in patients with rheumatoid arthritis and to evaluate their impact on cyclic adenosine monophosphate(camp), heme oxygenase-1(ho-1).

rheumatoid arthritis (ra) is characterized by the presence of hyperplastic synovium in association with immune-mediated inflammatory synovitis associated with chronic production of proinflammatory cytokines, which lead to cartilage and bone degradation .this study is a randomized, controlled double blind placebo-controlled ,prospective study to evaluate the potential therapeutic effects of cilostazol on synovial inflammation when administered as add-on treatments to the low dose of methotrexate. a total of 70 ra patients with active disease will be recruited from outpatient clinic of physical medicine, rheumatology and rehabilitation at mansoura university hospitals, mansoura, egypt will be included in the study. they will be diagnosed with ra according to the american college of rheumatology/european league against rheumatism criteria 2010 (the acr/eular 2010 criteria). ra patients who will meet the inclusion criteria will be enrolled in the study. they will be classified into two groups: group 1: 35 ra patients who will receive methotrexate and placebo for 12 weeks and serve as the control group. group 2: 35 ra patients who will receive methotrexate and cilostazol 50 mg twice daily for 12 weeks.

Eligibility criteria:
inclusion criteria: * patients with active rheumatoid arthritis (not in remission) according to american college of rheumatology/european league against rheumatism (acr/eular) 2010 criteria (13) i.e 28 joints disease activity score (das-28) \>2.6. * age range between 18 and 60 years old. * patients receive methotrexate; approximately the same doses of non steroidal anti-inflammatory drugs, selective cyclooxygenase-2 inhibitors, acetaminophen, and low dose of oral corticosteroids (prednisolone \< 15 mg) will be allowed to enroll the trial. * intravenous, intra-articular or intramuscular corticosteroids; intra articular hyaluronate sodium; biological dmards and other conventional dmards will not be permitted less than 4 weeks before the first dose of cilostazol. exclusion criteria: * patients with diabetes, congestive heart failure, other heart disease (arrhythmia, hypertension, ischemic heart diseases), severe anemia, bleeding problems, other inflammatory diseases, active infection, other illness except rheumatoid arthritis. * patients on low doses of aspirin * patients on anticoagulants. * patients with renal or hepatic diseases. * patients receiving oral prednisolone greater than 15 mg/day. * patients receiving biological dmards. * patients with hypersensitivity to study medications. * patients using antioxidants . * pregnant and lactating females.
peritumoral microbubbles and ceus for sln detection and biopsy in hnscc

Conditions: Sentinel Lymph Node; Head and Neck Squamous Cell Carcinoma

Summary: head and neck squamous cell carcinoma is the sixth most common malignant tumor in the world. cervical lymph node metastasis is frequently encounted on the date of diagnosis. surgical resection is one of the most important treatment methods for head and neck squamous cell carcinoma with or without lymph node metastasis. at present, for cn0 patients, prophylactic neck dissection is recommended for squamous cell carcinoma originating in suprglottic, hypopharyngeal and oropharyngeal areas et al. related studies reported that less than 30% of patients with cn0 were confirmed to have lymph node metastasis in postoperative pathological examination, who underwent neck dissection. unnecessary neck dissection may increase complication incidence, such as neurovascular injury, chylous leakage, sialosyrinx. accurate preoperative assessment is helpful to reduce unnecessary neck dissection. sentinel lymph node biopsy were proved to be effective in reducing prophylactic lymph node dissection in breast cancer, melanoma and other malignant tumors. compared with γ probe detection and indolyanine green injection, microbubble and contrast-enhanced ultrasound has no radiation and disturbance to resection margins in sentinel lymph nodes detection. furthermore, surgeons could conduct lymph node puncture biopsy simultaneously under ultrasound guidance, which can further minimize surgical trauma. at present, the role of microbubble and contrast-enhanced ultrasound in sentinel lymph node detection and biopsy is rarely reported in head and neck squamous cell carcinoma. this study aims to explore the accuracy of peritumoral microbubbles and contrast-enhanced ultrasound for sentinel lymph nodes biopsy in predicting cervical lymph node metastasis in head and neck squamous cell carcinoma.


Eligibility criteria:
inclusion criteria: * aged 18-70; * pathological biopsy indicated head and neck squamous cell carcinoma; * mr/ct examination indicate no suspected cervical lymph node metastasis; * the patient intent to perform primary focal resection and unilateral/bilateral neck dissection at our center; * agree to participate in clinical trials and sign informed consent. exclusion criteria: * allergic to microbubbles contrast agents; * patients who cannot tolerate surgery; * enlarged cervical lymph node in palpation or suspected cervical lymph node metastasis indicated in mr/ct examination; * distant metastasis.
correlations phenotype / genotype in down syndrome

Conditions: Down Syndrome

Summary: the purpose of this study is to correlate phenotype and genotype of down syndrome patients in order to identify the biochemical reactions involved in their mental retardation and their other phenotypic characteristics.


Eligibility criteria:
inclusion criteria: * down syndrome patients * age: 8years and older * assessment by the psychometric tests * possible blood tests exclusion criteria: * no exclusion criteria

Keywords: down syndrome phenotype genotype patient family
eccentric resistance training among individuals with chronic heart failure

Conditions: Heart Failure

Summary: to determine the effects of eccentric resistive training on ventricle functions and aerobic capacity as compared to a resistance and aerobic training among heart failure (hf)


Eligibility criteria:
inclusion criteria: * patient able to safely perform lower limb exercise will be check by six- minute walk test (6 mwt) * diagnosis of chronic hf and currently on optimal medical therapy exclusion criteria: * already participating in cardiac rehabilitation * new york heart association (nyha) classification of hf class iv hf symptoms * co-existent other disease such as asthma/ copd/interstitial lung disease. * symptomatic second degree or third degree heart block. * ecg with uncontrolled ventricular arrhythmia * limited exercise ability due to neurologic or orthopedic impairments of the legs (will cross-check with 6 mwt)